ArticleArthritis research & therapy2021
Clinical phenotypes and prognostic factors of adult-onset Still's disease: data from a large inpatient cohort.
Article in Arthritis research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.Annals of the rheumatic diseases · 2024Guideline
- Methotrexate in Still's Disease: An Updated Perspective on Efficacy and Safety.Advances in therapy · 2026Review
- Unfolding dermatological spectrum of Still's disease: a cohort study from the International AIDA Network Still's Disease Registry.Rheumatology (Oxford, England) · 2026Article
- The progression of initial symptoms and its relationship with the clinical course in adult-onset Still's disease: from the KEIO-AOSD cohort.EULAR rheumatology open · 2025Article
- Adult-Onset Still's Disease in a 49-Year-Old Female in the UAE: A Case Report and Literature Review.Cureus · 2025Article
- Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.Drugs & aging · 2024Review
- Recent advances and evolving concepts in Still's disease.Nature reviews. Rheumatology · 2024Review
- Observational
- A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still's Disease: A Single-Center Retrospective Observational Study.Rheumatology and therapy · 2023Article
- The Spectrum of Still's Disease: A Comparative Analysis of Phenotypic Forms in a Cohort of 238 Patients.Journal of clinical medicine · 2022Article
- Adult-Onset Still's Disease-like Syndrome following COVID-19 Vaccination: A Case Report and Review of the Literature.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo define different clinical phenotypes and assess prognostic factors of adult-onset Still's disease (AOSD).
methodsOverall, 492 patients with AOSD seen between 2004 and 2018 at a single centre were retrospectively studied.
resultsOf these patients, 78% were female, and the median age at onset was 34 (25-49) years [median (25th-75th percentile)]. The median follow-up time was 7 (3-10) years [median (25th-75th percentile)]. Clinical manifestations at admission were used to subdivide patients with AOSD as follows: systemic inflammation (cluster 1), pure (cluster 2), and intermediate (cluster 3). Each subtype had distinct clinical manifestations and prognoses: cluster 1 (34.6%)-multiple organ manifestations, highest infection rate and mortality, and more than half of the patients with at least one relapse during follow-up; cluster 2 (21.3%)-exclusively female, rash and joint involvement, no internal organ involvement, no mortality, and most of the patients with a monocyclic course; and cluster 3 (44.1%)-less infection rate, no serious complications, and lower mortality rate. The 5- and 10-year survival rates after diagnosis were 92.4% and 86.9%, respectively. Independent risk factors for mortality were age at onset ≥50 (hazard ratio (HR): 6.78, 95% CI: 2.10-21.89), hepatomegaly (HR: 5.05, 95% CI: 1.44-17.70), infection (HR: 15.56, 95% CI: 5.88-41.20), and MAS (HR: 26.82, 95% CI: 7.52-95.60).
conclusionThree subtypes of AOSD were identified with distinct clinical manifestations and prognoses. Age at onset ≥50, hepatomegaly, infection, and MAS were prognostic factors for AOSD mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.